Anastasiya Aleksandrovna Semenova

Anastasiya Aleksandrovna Semenova

Auto-generated profile, based on publicly available information

Anastasiya Aleksandrovna Semenova

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 December 2019 in Oncohematology
Verified
Journal Article
Open access
EKE. V. Kovaleva
E. V. Kovaleva
TDT. Yu. Danzanova
T. Yu. Danzanova
GSG. T. Sinyukova
G. T. Sinyukova
EGE. A. Gudilina
E. A. Gudilina
PLP. I. Lepedatu
P. I. Lepedatu
FAF. M. Abbasbeyli
F. M. Abbasbeyli
Objective. The possibilities of ultrasound elastography of the lymph nodes as an additional technique for the intermediate control of treatment of patients with Hodgkin’s lymphoma are determined.Materials and methods. A prospective study included patients with a diagnosis of classical Hodgkin’s lymphoma with affected superficial lymph nodes. Patients underwent ultrasound elastography (compression elastography and shear wave elastography) of the enlarged lymph nodes before treatment and after two cycles of chemotherapy. The reasons for the ultrasound examination of superficial lymph nodes after the second chemotherapy cycle were: an earlier ultrasound examination with revealed changes in the superficial lymph nodes (in 100% of cases), preservation of the palpable formation in the projection of the superficial lymph nodes (in 56.9% of cases). Before ultrasound elastography of the studied group of patients, the positive dynamics after two cycles of chemotherapy was confirmed by PET/CT (Deauville scale 2—3).Results and conclusion. According to strain elastography, stiff heterogeneous (third type of elastogram) and stiff structure (fourth type of elastogram) of affected lymph nodes were noted in 53.5 and 42.3% of cases, respectively, before treatment. After two cycles of chemotherapy, these types of elastogram were 52.1 and 43.7% of cases, respectively. According to the results of shear wave elastography before and after treatment, a decrease in the average shear wave velocity in the affected lymph nodes from 2.67 + 0.69 to 2.21 + 0.40m/s (p = 0.000003) was revealed.

18 April 2020 in Oncohematology
Verified
Journal Article
Open access
PDF file
LGL. Yu. Grivtsova
L. Yu. Grivtsova
VLV. V. Lunin
V. V. Lunin
ASA. A. Semenova
A. A. Semenova
VLV. B. Larionova
V. B. Larionova
GTG. S. Tumyan
G. S. Tumyan
ЛГЛ. Ю. Гривцова
Л. Ю. Гривцова
The minimum residual disease (MRD) for hematopoietic and lymphoid systems tumors is an important component of patient examination during therapy. The MRD detection is performed to evaluate the effect of therapy and risk stratification during chemotherapy (acute leukemia) or at the end of it (peripheral B-cell lymphomas). The main laboratory methods for MRD assessing are molecular (polymerase chain reaction) and immunological (multi-parameter flow cytometry (FC)) methods. Immunological evaluation of MRD is the standard of clinical protocols for the treatment of childhood acute lymphoblastic leukemia during induction therapy. In the case of acute leukemia in adults, MRD assessment is usually performed at the end of the consolidation course. Clinically significant and practically standardized is the immunological assessment of MRD in B-cell chronic lymphocytic leukemia.In multiple myeloma (in World Health Organization (2016) classification – plasma cell myeloma (PCM)), work is also underway to standardize protocols and unify approaches to MRD detection. With the introduction of new drugs and treatment regimens, as well as transplantation clinical outcome of patients significantly improved and MRD value is considered as a prognostic factor. To date, the use of the MRD value as a biomarker of treatment response in PCM has been approved by the US Food and Drug Administration.With the accumulation of our knowledge regarding the MRD and to establish the clinical significance of the FC in PCM, International Multiple Myeloma Study Group (IMWG) in 2011 was added the following definition to the traditional criteria of PCM complete remission: “Immunophenotypic complete remission” – the immunophenotypically absence of aberrant clonal plasma cells in the bone marrow when analyzing at least 1 million myelocaryocytes using a multiparameter FC (4 or more parameters).This article discusses the evolution of immunological approaches using a multi-parameter FC to detect MRD in patients with PCM in accordance with various existing protocols, features of the preanalytical stage and general rules for FC detection of MRD in PCM.

19 July 2022 in Oncohematology
Verified
Journal Article
Open access
PDF file
AMA. A. Mamedova
A. A. Mamedova
NMN. E. Mochkin
N. E. Mochkin
VSV. O. Sarzhevskiy
V. O. Sarzhevskiy
EDE. A. Demina
E. A. Demina
VBV. S. Bogatyrev
V. S. Bogatyrev
ЮЗЮ. Р. Залялов
Ю. Р. Залялов
Aim. To study the efficacy and safety of combined immunochemotherapy according to the DHAp protocol + nivolumab in patients with refractory/relapsed classical Hodgkin's lymphoma before autologous hematopoietic stem cell transplantation.Materials and methods. The study consisted of 2 phases: 1st - immunotherapy with nivolumab (2 injections as monotherapy at a dose of 240 mg/day with 14 days interval); 2nd - combined immunochemotherapy according to the DHAp protocol + nivolumab (14 days after the 2nd administration of nivolumab): nivolumab 480 mg/day on day 1 in combination with chemotherapy according to the DHAp protocol, 4 cycles in total. The effectiveness of therapy was evaluated after 2 injections of nivolumab, after 2 and 4 cycles of combination therapy. from March 2020 to November 2021, 32 patients were included in the study. The median age was 34 (18-55) years.Results. As of November 2021, the result was evaluated in 32 patients after the 1st stage of treatment (nivolumab monotherapy). A complete response was obtained in 4 (12.5 %) patients, a partial response in 20 (62.5 %) patients, disease stabilization was noted in 5 (16 %) patients, an indeterminate response in 3 (9 %) patients. At the 2nd phase, the efficacy after the 2nd cycle of DHAp + nivolumab was evaluated in 31 patients (complete response was obtained in 19 (61 %), partial response in 11 (36 %)); the final efficacy evaluation (after the 4th cycle of DHAp + nivolumab) was performed in 30 patients, and all patients achieved response to therapy (complete response in 25 (83 %), partial response in 5 (17 %)). 2 patients were excluded from the study.Conclusion. preliminary results of combined immuno- and chemotherapy according to the DHAp protocol showed high efficacy and relatively low toxicity in patients with refractory/relapsed classical Hodgkin's lymphoma before autologous hematopoietic stem cell transplantation.

3 September 2024 in Oncohematology
Verified
Journal Article
Open access
PDF file
OOO. A. Obukhova
O. A. Obukhova
IKI. A. Kurmukov
I. A. Kurmukov
ASA. A. Semenova
A. A. Semenova
ALA. V. Lebedeva
A. V. Lebedeva
AIA. S. Ivanova
A. S. Ivanova
NSN. Yu. Shagina
N. Yu. Shagina
Background. Assessing nutritional status at the start of treatment for patients with diffuse large B-cell lymphoma allows us to plan adequate accompanying treatment for patients in whom early nutritional support can improve the results of antitumor treatment.Aim. To assess the prevalence of nutritional deficiency, features of usual diet energy and protein composition in patients with diffuse large B-cell lymphoma who are starting antitumor treatment.Materials and methods. The study included 96 adult patients (m = 61), average age 38.9 ± 16.8 years, with newly diagnosed diffuse large B-cell lymphoma of various localization and prevalence. Additional laboratory screening (total protein, albumin, C-reactive protein (CRP), total cholesterol, triglycerides, daily urea excretion), anthropometric measurements (height, body weight (BW), weight loss over 6 months, body mass index), questionnaire (considering the intake of nutrients during the previous 3 days, calculating the intake of protein and energy, nitrogen balance) were performed in all patients before the first course of antitumor treatment. GLIM (Global Leadership Initiative on Malnutrition) criteria were used to diagnose protein-energy malnutrition (PEM).Results. In studied patients, energy intake was 27.92 ± 6.47 kcal/kg BW per day, protein 0.91 ± 0.18 g/kg BW per day, and nitrogen balance was –3.57 ± 2.94 g/day. Moderate PEM was diagnosed in 37 (38.5 %) patients. Differences in some laboratory parameters were revealed in patients with PEM and without nutritional disorders: CRP level (20.38 ± 14.69 mg/L versus 12.52 ± 5.66 mg/L; p = 0.0004), glucose (5.07 ± 1.09 mmol/L versus 4.57 ± 0.62 mmol/L; p = 0.005), total cholesterol (4.35 ± 1.27 mmol/L versus 5.36 ± 1.45 mmol/L), triglycerides (1.22 ± 0.51 mmol/L versus 2.02 ± 0.78 mmol/L; p = 0.001).Conclusion. Moderate PEM is detected in more than a third of patients with diffuse large B-cell lymphoma who begin antitumor treatment. The leading symptom in this case is unintentional weight loss over the past 6 months. An increased CRP level, moderate hyperglycemia, and lower concentrations of total cholesterol and blood triglycerides also characterize PEM in this cohort of patients. With sufficient energy supply, the amount of protein in the natural diet of patients with PEM turned out to be low, and the nitrogen balance was negative, which in the future can lead to the development of sarcopenia and requires nutritional support.

18 April 2020 in Oncohematology
Verified
Journal Article
Open access
PDF file
EKE. V. Kovaleva
E. V. Kovaleva
TDT. Yu. Danzanova
T. Yu. Danzanova
GSG. T. Sinyukova
G. T. Sinyukova
EGE. A. Gudilina
E. A. Gudilina
PLP. I. Lepedatu
P. I. Lepedatu
ASA. A. Semenova
A. A. Semenova
Objective: to evaluate the possibilities of ultrasound elastography for differentiation of reactive and lymphomatous superficial lymph nodes (LN).Materials and methods. The prospective study included 138 patients with enlarged superficial LN. Based on a previous histological examination, patients were divided into two groups: 1st group (n = 108) – patients with non-Hodgkin’s lymphomas and Hodgkin’s lymphoma; 2nd (n = 30) – patients with reactive (inflammatory) changes in superficial LN. All patients underwent ultrasound elastography of the enlarged LN using ARFI technology.Results. According to the results of ultrasound elastography, the average, minimum, and maximum shear wave velocities for enlarged LN in lymphoma (1st group) were 2.616 ± 0.684; 1.980 ± 0.557 and 3.351 ± 0.987 m / s, respectively; for LN with reactive changes (2nd group) – 1.704 ± 0.223; 1.414 ± 0.209 and 2.027 ± 0.261 m / s, respectively. Thus, the average, minimum, and maximum values of shear wave velocities significantly different between the groups (p ˂0.001). The cut off values of the average shear wave velocity in the differential diagnosis of lymphoma and hyperplasia are determined at the level of 2.05 m / s, with a sensitivity of 88.5 %, specificity of 100 %, and AUC of 0.942 (p ˂0.001).Conclusion. Ultrasound elastography demonstrated statistically significant differences in shear wave velocity in the enlarged superficial LN in lymphoma and in inflammatory processes that can be used as a preliminary non-invasive differential diagnosis of enlarged superficial LN in these conditions.

1 October 2021 in Journal of oncology: diagnostic radiology and radiotherapy
Verified
Journal Article
Open access
PDF file
AFA. N. Fedotov
A. N. Fedotov
DSD. V. Sashin
D. V. Sashin
APA. I. Pronin
A. I. Pronin
ASA. A. Semenova
A. A. Semenova
EKE. A. Kobyakova
E. A. Kobyakova
NGN. V. Garanina
N. V. Garanina
Intracranial hypotension is a clinical and radiological syndrome, manifested by a decrease in the volume or pressure of the cerebrospinal fluid caused by various reasons, one of the main clinical manifestations of which are orthostatic headaches. The gold standard in the radiation diagnosis of this condition is magnetic resonance imaging (MRI). Increasing the awareness of radiologists about this pathology, its manifestations on MRI, will allow more often to diagnose this syndrome and choose the tactics of further treatment. This publication presents its own clinical observation — a patient with intracranial hypotension syndrome, on his example, MR and clinical manifestations are considered, and some data on the etiology and pathogenetic mechanisms of the described pathological process are also given.